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Abstract 
Background: Attention-Deficit Hyperactivity Disorder (ADHD) is linked to 
increased risk for substance use disorders (SUDs) and nicotine dependence. 
Aim: To examine the effects of stimulant treatment on subsequent risk for SUD and 
nicotine dependence in a prospective longitudinal ADHD case-control study. 
Method: ADHD, conduct disorder (CD) and oppositional defiant disorder (ODD) 
were assessed at baseline. SUDs, nicotine dependence and stimulant treatment were assessed 
retrospectively after a mean follow-up of 4.4 years, at a mean age of 16.4 years. 
Results: Stimulant treatment of ADHD was linked to a reduced risk for SUDs 
compared to no stimulant treatment, even after controlling for CD and ODD (HR=1.91; 
95%CI=1.10-3.36), but not to nicotine dependence (HR=1.12; 95%CI=.45-2.96). Within the 
stimulant-treated group, a protective effect of age of first stimulant use on SUDs development 
was found, which diminished with age, and seemed to reverse around the age of 18. 
Conclusions: Stimulant treatment appears to lower the risk for developing SUDs and 
does not impact the development of nicotine dependence in adolescents with ADHD. 
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Numerous studies have shown an increased risk to develop substance use disorders (SUDs) 
and nicotine dependence in patients with Attention-Deficit Hyperactivity Disorder (ADHD). 
A recent meta-analysis showed that a childhood diagnosis of ADHD increased the risk of 
developing SUDs and nicotine use (1). While some studies suggest that the increased risk of 
developing SUDs in ADHD is completely dependent on the presence of comorbid Conduct 
Disorder (CD)/Oppositional Defiant Disorder (ODD) (2-3), other studies found that ADHD 
remains a risk factor after adjustment for CD/ODD (4-6). The risks described are substantial 
and emphasize the need for early intervention to prevent these negative outcomes of a 
childhood diagnosis of ADHD. Stimulant therapy is the first choice medication treatment in 
participants with ADHD (7). Since stimulants have the potential to be addictive drugs, 
concerns have been raised regarding the effects of stimulant treatment on the later 
development of SUDs in ADHD (8). These concerns are mainly based on the sensitization 
hypothesis. This theory states that exposure to stimulants alters the dopamine system in such 
a way that an increased sensitivity is established to the reinforcing effects of previously 
experienced drugs. This, in turn, may result in an increased risk of developing SUDs and 
nicotine dependence. Interestingly, all evidence for this hypothesis comes from animal studies 
(9). So far, the harmful effect predicted by the sensitization hypothesis on the development of 
SUDs has only been reported by a single study in humans (10). It should be noted that the 
results of that study may have been confounded by a larger number of participants with 
comorbid CD in the stimulant-exposed group as compared to the stimulant-naïve group. An 
alternative hypothesis to the sensitization hypothesis posits that stimulant treatment protects 
against SUDs and nicotine dependence by decreasing the core symptoms of ADHD (e.g. 
impulsivity and poor planning) and associated problems (e.g. poor self-esteem, school failure, 
academic or occupational failure) that lead to drug, alcohol, and nicotine use (11). This 
hypothesis is supported by several studies (e.g., 12, 13) and a meta-analysis (11) that showed 
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protective effects of stimulant treatment on the later development of nicotine use and SUDs. 
Interestingly, some studies, that evaluated participants at a higher mean age, did not find any 
effect of stimulant treatment on the development of SUDs and nicotine dependence (14-16). 
Meta-analytic evidence suggests that the protective effect of stimulant treatment is indeed 
much larger in adolescence (OR: 5.8), than in early adulthood (OR: 1.4) (11). Several other 
factors might influence the effects of stimulant treatment on SUDs. One study found that 
stimulant therapy only influences the development of substance abuse in boys, but not girls 
(12). However, a different study also found this effect in girls (17). Furthermore, an earlier 
age of stimulant initiation (18) and a longer duration of stimulant use (16) have been reported 
to have a protective effect on the development of SUDs; however, another study did not 
replicate these findings (13, 19).  
To our present knowledge we are the first prospective, longitudinal study of European 
origin investigating the effect of stimulant medication on the development of SUD and 
nicotine dependence in ADHD. The current study describes a four-year follow-up of a large 
sample of well-defined probands with combined type ADHD, their affected siblings and 
healthy controls. Our aim was to assess the effects of stimulant treatment on the development 
of SUDs and nicotine dependence. We also sought to assess the effects of specific 
characteristics and moderators of stimulant treatment (e.g. age of treatment initiation, duration 
of treatment, cumulative dose) on the development of SUDs and nicotine dependence. 
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Method 
Individuals participating in this study were recruited as part of the Belgian (n=41), 
Dutch (n=537) and German (n=21) International Multicenter ADHD Genetics (IMAGE) 
study (20). ADHD probands aged 5 to 17 years had been recruited from outpatient clinics at 
the data collection sites between 2003 and 2006. Participants had to be Caucasians of 
European descent. Exclusion criteria applying to both probands and siblings included autism, 
epilepsy, IQ < 70, brain disorders, and any genetic or medical disorder associated with 
externalizing behaviors that might mimic ADHD. In addition, healthy control-participants 
were recruited from primary and high schools from the same geographical regions as the 
participating ADHD-families. 
In 2008 and 2009 participants were re-invited to participate in the current follow-up 
study, on average 4.4 years (s.d.=.7) after study entry. A total of 505 participants with a 
baseline diagnosis ADHD (both probands and affected siblings) and 223 healthy control 
participants above the age of 12 participated in the follow-up. For 599/728 (82.3%) of these 
children, information on medication use history were available (i.e. rating of medication use 
(yes or no) was available). Ethical approval for the study was obtained from the National 
Institute of Health registered ethical review boards for each center. After a complete 
description of the study, written informed consent was obtained from both parents and 
children. 
Assessment of ADHD, ODD, and CD at baseline 
Baseline measures included the Long Version of Conners’ Parent (CPRS-R:L), and 
Teacher Rating Scale (CTRS-R:L; 21), which were used to quantify ADHD symptoms. 
Parents and teacher were asked to describe the child’s behavior in a medication-free period 
when filling out the questionnaire. For a full account of the measures used in IMAGE, please 
see Müller et al (22). T-scores ≥ 63 on the Conners ADHD subscales (L, M and N) were 
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considered clinical. The CPRS-R:L also assesses symptoms related to ODD (e.g. angry and 
resentful, argues with adults, loses temper, irritable, temper outbursts) on a 4-point ordinal 
scale.  
The Parental Account of Childhood Symptoms (PACS; 23) interview was 
administered if scores on the Conners ADHD rating scales were considered clinical. The 
PACS is a semi-structured, standardized, investigator-based interview developed to provide 
an objective measure of child behavior. A trained interviewer administered the PACS to the 
parents, who were asked for detailed descriptions of the child’s typical behavior in a range of 
specified situations. Among others, the PACS covers the Diagnostic and Statistical Manual of 
mental disorders (DSM-IV; 24)) symptoms of ADHD, CD and ODD (for an exact description 
of the interview procedure, we refer to 20). 
Categorical measures of ADHD, ODD, and CD were created. ADHD was defined 
using a standardized algorithm applied to combine symptom counts on the PACS and CTRS-
R:L, both providing operational definitions of each of the 18 behavioral ADHD symptoms 
defined by the DSM-IV (24). ADHD symptom count was used as a measure of ADHD-
severity. Situational pervasiveness of ADHD was defined as at least two symptoms being 
present in two or more different situations as assessed with the PACS interview, as well as the 
presence of one or more items scored as 2 or 3 or more from the ADHD scale of the CTRS-
R:L. ODD and CD were defined according to the DSM-IV (24) criteria based on information 
from the PACS.  
Follow-up Measures 
A parental report of SUDs was obtained using the Substance use disorder module of 
the Diagnostic Interview Schedule for Children (DISC-IV-P; 25). The DISC-IV-P was 
administered by telephone interview, and scored with a computer-based algorithm to derive 
DSM-IV-defined SUD diagnoses. Age of first substance use was assessed in the interview. 
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Participants above the age of 12 completed a number of questionnaires. The Alcohol Use 
Disorders Identification Test (AUDIT; 26) was completed by participants. This questionnaire 
was used to identify self-reported alcohol dependence. Scores on the AUDIT may range from 
0-40. A score of 9 or higher was used to define alcohol abuse, and a score of 13 or more in 
girls and 15 or more in boys was used as a cut-off to define alcohol dependence (26). The 
Drug Abuse Screening Test–20 (DAST; 27) was used to assess drug use disorders. Scores on 
this questionnaire may range from 0 – 20. A cut-off of 5 was used to identify possible drug 
use disorders (27). The Fagerström test for Nicotine Dependence (FTND; 28) was used to 
assess nicotine dependence. Scores on this questionnaire may vary between 0 and 10. A cut-
off of 6 was used to identify nicotine dependence (28). Age of first nicotine use was also 
assessed in this questionnaire.  
To create best estimate diagnoses of SUDs, these were considered present if scores on 
either self- or parent-report measures met criteria as stated above. We created summary 
diagnostic groups to aggregate diagnostic information across instruments and informants. For 
Alcohol Use Disorder (AUD), the AUDIT and alcohol module of the DISC-IV-P were used, 
for Drug Use Disorder (DUD), the DAST and the marihuana and other drugs module of the 
DISC-IV-P were used. AUD and DUD were collapsed into one category to form an overall 
measure of SUDs, to increase reliability of the measure and reduce the number of statistical 
tests. For nicotine dependence the FTND and the tobacco module of the DISC-IV-P were 
used. Two main dependent variables were used: an overall measure of SUDs and one measure 
of nicotine dependence. 
Medication history was assessed using parental report of medication use combined 
with pharmacy records. Predictors derived from this information are previous and/or current 
stimulant use (yes/no), current use of stimulants (currently on medication yes/no), age at 
stimulant treatment initiation, age-adjusted duration of stimulant use (defined as the 
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percentage of time treated with stimulants since the onset of ADHD), and age-adjusted 
cumulative dosage of stimulants (defined as dosage corrected for number of days since the 
onset of ADHD). 
Statistical analyses 
All analyses were conducted using SPSS (IBM SPSS Statistics version 20). 
Differences between groups in gender, age, IQ, ADHD-severity, and ODD/CD comorbidity 
were examined using analysis of variance and chi-square tests. Differences between subjects 
successfully followed- up and those lost to follow-up in gender, age ADHD-severity, and 
ODD/CD comorbidity were examined using t-test and chi-square tests.  
The possible effects of stimulant treatment on the development of drug and alcohol-
related SUDs and nicotine dependence were studied using, cox-proportional hazard models . 
The models used age of first substance use as the survival time for the cases (classified as 
having an SUD and/or nicotine dependence) and current age as the time of censoring for the 
non-cases. Correction for clustered (family) data was done using robust standard errors (29). 
Three groups were included in this analysis: participants with a childhood diagnosis of ADHD 
who were stimulant-naïve (n = 30) and participants with a short or inconsistent history of 
stimulant medication never exceeding 12 months (n = 31; n=61 no-stimulant treatment 
group); participants with childhood diagnoses of ADHD with a history of stimulant 
medication longer than 12 months (n=327; stimulant treatment group), and healthy control 
participants (n=211).  
Differences in the number of SUD and nicotine dependence between the subjects from 
Germany (n= 21), Belgium (n= 41), and the Netherlands (n = 537) were examined using 
generalized estimated equations (GEE;30), robust estimators and exchangeable structure for 
working correlation matrices.  
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Within-group analyses were performed to evaluate the potential subtle effects of 
stimulant medication had on the development of SUDs and nicotine dependence. A logistic 
regression model was fitted using GEE (30), robust estimators and exchangeable structure for 
working correlation matrices. All participants with a childhood diagnosis of ADHD and any 
history of stimulant medication were included in these analyses (n= 358). Any SUD or 
nicotine dependence were used as the dependent measure. Our data-analytic approach was 
similar to that suggested by Hosmer and Lemeshow (31). In short, several steps were taken to 
identify potential predictors of SUDs and nicotine dependence: i) initially, all possible 
predictor and possible confounding variables (i.e. current use of stimulants, age at stimulant 
treatment initiation, age-adjusted duration of stimulant use and age-adjusted cumulative 
dosage of stimulants, ADHD, ODD and CD symptom count at baseline, gender and age at 
follow-up) were analyzed using a univariate approach. Correlations between predictor 
variables were calculated to assess whether the assumption of multicollinearity (r>.80) was 
violated; ii) all predictors with a p-value <.20 and variables with known clinical importance 
were included in a multivariate model; iii) predictors with p-values>.05 were dropped from 
the model if this positively influenced the overall fit of the model. To assess the fit of the 
model the quasi-likelihood under independence model criterion (QIC) was used (32). We will 
refer to this model as the initial main effects’ model; iv) we checked whether any meaningful 
interactions among the main effects improved the fit of the model. 
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Results 
Attrition and Demographics Characteristics  
At baseline, among ADHD and control participants, there were no significant 
differences between those successfully followed up and those lost to follow-up on age (t= 
.196, p=.845) and gender (χ2= 3.412, p=.065). At baseline, no differences were found among 
ADHD participants followed up and those lost to follow-up on ADHD-severity (t= 1.533, 
p=.126), and presence of CD (χ2=114, p=.735) and ODD (χ2= .089, p=.766). No differences 
were found in the number of SUD and nicotine dependence between the subjects from 
Germany , Belgium, and the Netherlands (respectively Wald χ2= 3.379, p= .337 and Wald χ2= 
3.677, p= .299). Table 1 describes demographic and clinical features of the three groups 
(healthy controls, no-stimulant treatment and stimulant treatment group). The stimulant and 
no-stimulant groups did not differ in the number of participants who met criteria for ODD or 
CD, none of the healthy control participants were assessed for ODD or CD. The three groups 
did not differ in current age. Controls had a significantly higher IQ than the stimulant ADHD 
group. Furthermore, the stimulant and no-stimulant groups differed in ADHD severity, in that 
the no-stimulant group had lower ADHD symptom counts. ADHD symptom count was 
assessed over a medication-free period. Finally, stimulant treated ADHD participants were 
more likely to be male. In the subsequent Cox proportional hazard models we therefore 
statistically adjusted for gender and current age. Although no difference was found between 
the ADHD groups in the prevalence of ODD and CD, separate models, including the no-
stimulant and stimulant treatment groups, were built that corrected for ODD, CD and ADHD-
severity, to completely rule out their effects. 
 
**********************insert table 1 about here******************* 
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 Overall effect of stimulant medication 
Table 2 displays prevalence rates and hazard ratios for SUDs and nicotine dependence 
for the healthy control, no-stimulant treatment and stimulant groups. The no-stimulant 
treatment group had a 2.6 times higher risk of developing an SUD when compared to healthy 
control participants, and had a 2 times higher risk of developing an SUD than the stimulant 
treatment group. No significant differences were found between the stimulant treatment and 
the healthy control group (also see left panel Fig.1). Both the stimulant treatment (HR = 3.56) 
and the no-stimulant treatment group (HR= 3.83) had an increased risk of developing nicotine 
dependence compared to healthy control participants. No differences were found between the 
no-stimulant treatment and stimulant treatment group in their risk for nicotine dependence 
(also see right panel Fig. 1).  
 
**********************insert table 2 about here******************* 
 
Analyses between the stimulant treatment and the no-stimulant treatment group were 
rerun including ODD, CD, and ADHD severity at baseline as covariates, to rule out any role 
of these measures on the observed protective effect of stimulant treatment on the development 
of SUDs. The control group was not included in these analyses because the PACS was not 
administered if scores on the CPRS-R;L and CTRS-R;L were not considered clinical (for an 
exact description of the interview procedure, we refer to 20). Results remained essentially 
unchanged: the protective effect of stimulant treatment on the development of SUDs proved 
not to be dependent on ODD, CD, or ADHD severity (no- vs. stimulant treatment; HR=1.91; 
95% CI =1.10-3.36), neither did results concerning nicotine dependence (no- vs. stimulant 
treatment (HR=1.12; 95% CI =.45-2.96).  
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**********************insert Figure1 about here******************* 
 
Predictors of SUDs and Nicotine Dependence in Stimulant-treated Participants 
Correlations and results of the univariate analyses are displayed in Table 3. In the 
initial main effects’ model for SUDs, seven main effects were retained, namely: current age, 
age of first stimulant use, treatment delay, current use of stimulants, ODD, CD and gender. 
Because treatment delay and age of first stimulant use were highly correlated (r=.83), two 
models were built including all main effects and either age of first stimulant use or treatment 
delay. The main effects’ model with the best fit indicated by QIC was the model including age 
of first stimulant use, ODD and current age. Evaluation of this model showed that including 
ODD, age of first stimulant use, current age, the interaction between age of first stimulant use 
and current age led to the most parsimonious model (QIC= 217.79). The protective effect of 
earlier age of first stimulant use on the development of an SUD was found to decrease with 
increasing age (OR=.95, Wald χ2 =13.78, p<.001), see Fig.2.  
 
**********************insert Figure2 about here******************* 
 
The initial main effects’ model for nicotine dependence retained 5 possible predictors: 
current age, age of first stimulant use, age-adjusted duration of stimulant use, current use and 
symptom count at baseline. It appeared that including current age and age-adjusted duration 
of stimulant use led to the most parsimonious model (QIC= 163.66). Higher current age was 
significantly related to an increased risk of developing nicotine dependence (OR=1.17, Wald 
χ2 =10.89, p=.001), while percentage of time treated was not significantly associated with risk 
of developing nicotine dependence (OR=.99, Wald χ2 =3.77, p=.052).  
 
15 
 
Discussion 
The current study investigated the effects of stimulant medication on the development 
of alcohol- and drug-related SUDs and nicotine dependence in ADHD. A protective effect of 
stimulant therapy on the development of the SUDs was found. No difference was found in the 
risk of developing SUD between the stimulant therapy group and the healthy controls, 
suggesting normalization. In contrast, no difference in the risk of developing nicotine 
dependence was found between participants not treated with stimulants and participants who 
were treated. Specific moderators were investigated in order to further unravel the 
mechanisms through which stimulant use influences the later development of SUDs. It was 
found that children who start stimulant medication at a younger age are better protected 
against the later development of SUDs. However, the effect of age of first stimulant use on 
SUD development diminished with age, and seemed to reverse around the age of 18.  
Our results argue against the sensitization hypothesis. This hypothesis states that 
stimulant therapy would increase the risk of developing SUDs and nicotine dependence in 
ADHD, by increasing the sensitivity to substances, through alterations in the dopamine 
system. Rather, our results support previous findings that stimulant therapy has a protective 
effect on the development of SUDs (11-13). The protective effect of stimulant treatment on 
the development of SUD could not be explained in terms of the impact of comorbid ODD or 
CD symptoms and ADHD-severity, as findings remained essentially unchanged when 
adjusting for these possible confounds. Furthermore, we found that the stimulant treatment 
group did not significantly differ in the risk of developing SUDs compared to healthy control 
participants, while the no-stimulant treatment group did. This suggests normalization of the 
risk of developing SUDs in the stimulant treatment group, but not in the no-stimulant group. 
As outlined above, possibly, stimulant treatment may protect against SUDs by decreasing the 
core symptoms of ADHD (e.g. impulsivity) and associated problems (e.g. poor self-esteem, 
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school failure, academic or occupational failure) that may lead to drug and alcohol use (11). 
Although our results show a less robust protective effect of stimulant therapy on the 
development of SUDs (HR: 2.12) than indicated by an earlier meta-analysis by Wilens et al 
(33) (HR: 5.8), our findings are of great clinical significance. The present study shows that 
stimulant-treated participants are twice less likely to develop SUDs than participants that did 
not receive stimulant treatment. 
Interestingly, previous studies have shown that the protective effect of stimulant 
treatment on the development of SUDs is much stronger in adolescence (4, 12-13) than in 
adulthood (14-15). This might mean that SUD development is delayed rather than being 
altered by stimulant treatment. The present study reports on an adolescent sample (mean 
age=16.4), and we can therefore not draw firm conclusions about the effect of stimulant 
therapy on SUDs in adulthood. We did find, however, that the protective effect of age of first 
stimulant use was only true for children up to 18, and that the risk of developing SUDs may 
even reverse around the age of 18 (Fig.2). Apart from the direct effect of stimulant medication 
on the development of SUDs, an alternative explanation of our findings is possible. 
Participants who start stimulant medication early might have greater parental support, 
however, this parental support may diminish once the individual reaches adulthood. Indeed, 
parental support has been found to be inversely related to substance use in a large sample of 
high school students (34). Clearly, future studies are warranted to assess whether parental 
support mediates the protective effect of stimulant therapy on the development of SUDs. 
While we did find a protective effect of stimulant use on the development of SUDs, 
such a protective effect was not found on the development of nicotine dependence. This is in 
accordance with another study that also failed to find a protective effect of stimulant use on 
nicotine dependence, but did find a protective effect on SUDs (35). Other studies did find 
protective effects on smoking initiation and regular smoking (e.g., 13,  17, 36), but these 
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studies did not look at nicotine dependence. These findings suggest that stimulant therapy 
does have a protective effect on the early stages (initiating and regular smoking) of nicotine 
dependence, while there is no effect on later stage of full onset nicotine dependence. 
However, due to the relatively low number of subjects with nicotine dependence in our 
sample (7%), caution should be taken when interpreting the null findings concerning nicotine 
dependence. Overall, the relationships between ADHD and related externalizing disorder, and 
nicotine dependence and substance use appear to be complex. ADHD is associated with 
earlier initiation of smoking and higher rate of regular smoking, and longitudinal twin 
modeling indicates that the covariance between ADHD and smoking is foremost due to 
common environmental risk factors (37). Covariance between smoking and substance use was 
due to both additive genetic and common environmental influences. Further, about half of the 
covariance between externalizing disorders and substance use was due to shared genetic and 
half due to shared environmental factors (37). According to the gateway theory, smoking 
precedes use of substances in many cases (38). However, in a minority of cases, evidence for 
a reverse gateway is found in that marihuana users had a higher risk for subsequent tobacco 
use (38). Future prospective studies on the specific trajectories from first nicotine use to 
nicotine dependency, in ADHD medication treated and medication naïve patients, are 
warranted to further elucidate the effects of stimulant treatment on the development of 
nicotine dependence.  
Our findings should be viewed in the light of some limitations. First of all, our study 
design is naturalistic and non-randomized. This makes it impossible to control for all possible 
confounding factors. The best method of determining the effect of stimulant medication on 
the development of SUDs and nicotine dependence would be a randomized controlled trial. 
However, due to practical and ethical issues such studies are not feasible. The current study 
design makes it difficult to draw conclusions on causality and one should be cautious in 
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interpreting the results. Second, participating participants were of Caucasian descent, which 
limits the possibility to generalize our results to other ethnicities. Furthermore, we did not 
have clinicians make diagnostic judgments but used multiple measures and multiple 
informants to assess substance and nicotine use and abuse. This approach might have 
influenced our estimates of the prevalence. Finally and importantly, our no-stimulant treated 
ADHD group was relatively small compared to the stimulant-treated group, which may have 
reduced the power of our analyses or the generalizability of our results. 
Despite these limitations, our large sample of well-defined participants with ADHD 
provided us with a unique opportunity to examine the relationship between treatment with 
stimulant medication and SUDs and nicotine dependence in a large European sample. This 
study adds two important insights to the available literature. First, we found that the elevated 
risk of drug- and alcohol-related SUDs and nicotine dependence in ADHD could not be 
attributed to the use of stimulant medication. Stimulant treatment has a protective effect on 
the development of drug- and alcohol-related SUDs. Furthermore, we showed that early age 
of stimulant treatment initiation had a protective effect on the development of SUDs, but that 
this effect appears to reverse after the age of 18.  
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Table 1. Subject characteristics. 
 No ADHD ADHD    
 
Healthy 
Controls 
(n= 211) 
No- 
Stimulant 
Treatment 
(n= 61) 
Stimulant 
Treatment 
(n= 327) 
Test-value 
p-
Value 
Contrasts 
Gender (n 
males (%)) 
90 
(41.50) 
36 
(58.06) 
278 (85.00) Χ2=113.03 <.001 H<N<S 
Age 
16.31 
(2.49) 
16.57 
(2.78) 
16.42 (2.34) F=.30 .74 H=N=S 
IQ 
105.55 
(9.60) 
101.85 
(16.03) 
100.02 
(13.68) 
F=11.84 <.001 
H=N, 
N=S, H>S 
ADHD 
Symptom 
Count 
- 
14.58 
(3.27) 
15.88 (2.00) F=15.67 <.001 N<S 
ODD (%) - 15 (30.60) 120 (40) χ 2=1.57 .21 N=S 
CD (%) - 7 (14.30) 64(21.40) χ 2=1.31 .25 N=S 
Note. N = No Stimulant Treatment, S = Stimulant Treatment, H = Healthy controls, IQ= 
Intelligence Quotient. 
 
Table 2. Prevalence rates of substance use disorders and nicotine dependence in participants 
with ADHD with and without a history of stimulant therapy, and healthy controls. 
 Prevalence Rates 
 
Healthy Controls 
(n = 211) 
No-Stimulant Treatment 
(n = 61) 
Stimulant 
Treatment 
(n = 327) 
 n % n % n % 
Substance Use 
Disorders  
26 12.3 17 27.9 65 19.9 
Nicotine 
Dependence 
6 2.8 6 9.8 30 9.2 
       
 Hazard Ratios 
 No-Stimulant Treatment  
v.  
Healthy Controls 
No-Stimulant Treatment  
v. 
Stimulant Treatment 
Stimulant Treatment  
v.  
Healthy Controls 
 
HR 95% CI HR 95% CI HR 95% CI 
Substance Use 
Disorder 
2.60* 1.35-4.99 2.00* 1.11-3.63 1.30 .76-2.22 
Nicotine 
Dependence 
3.83* 1.11-13.28 1.07 .44-2.61 3.56* 1.28-9.88 
Note: Hazard Ratios were calculated using Cox proportional hazard regression. All 
comparisons were corrected for gender and current age. HR: Hazard Ratio. 95% CI: 
Confidence Interval.  
* Significant at p<.05 
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Fig. 1: Cumulative lifetime risk for any substance use disorder and nicotine dependence  
 
Note; Survival curves were calculated using Cox proportional hazard regression. All comparisons were corrected for gender and current age. 
SUD: Substance use disorder 
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Table 3. Bivariate correlations and univariate outcomes of possible predictors for substance use disorder and nicotine dependence 
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e 
D
o
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A
D
H
D
 
S
y
m
p
to
m
 
co
u
n
t  SUD 
Nicotine 
Dependence 
 
Wald 
 χ2  
p- 
value 
Wald 
 χ2 
p- 
value 
Current Age 1 .40* .17* -0.01 -.01 -0.03 .35* -.14* -.12* -.19*  57.19 <.001 15.88 <.001 
Age First Stimulant 
 
1 .14* 0.01 .11 -0.04 .83* -.60* -.37* -.22*  7.49 .006 10.07 0.002 
Current Use 
  
1 0.06 -.13* .16* .14* -.52* -.03 0.04  5.45 0.02 3.37 0.07 
ODDa    
1 -.04 -.38* 0.07 -.08 -.03 0.01  4.78 0.03 0.15 0.70 
Gendera     
1 -.12* 0.09 -.14 -.24* -.23*  2.82 0.09 0.07 0.79 
CDa      
1 -0.05 -0.02 0.01 -.23*  1.57 0.21 0.53 0.47 
Treatment Delay 
      
1 -.64* -.42* -.07  7.07 0.008 11.90 .001 
Age-Adjusted Duration  
       
1 .68* .17*  .83 0.31 5.67 0.02 
Age-Adjusted Cumulative Dosage  
        
1 .19*  .14 0.70 0.27 0.61 
ADHD Symptom count 
         
1  0.14 0.74 0.86 0.35 
Note. Correlations were calculated using Pearson correlation coefficient except for: aCorrelations calculated using Spearman Rank Correlation  
* Significant at p<.05 
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Fig.2. Predicted probability of substance use disorders within stimulant-treated participants 
with ADHD 
 
Note; Predicted probability of substance use disorder according to GEE model, that included 
age, gender, and age of first stimulant use age*age of first stimulant use. Below average age 
of first stimulant use; participants started before age 8.1 years, above average age of first 
stimulant use; participants started after age 8.1 years. 
